RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-6.86 Insider Own1.70% Shs Outstand69.52M Perf Week-6.25%
Market Cap3.27B Forward P/E- EPS next Y-5.64 Insider Trans-3.12% Shs Float66.86M Perf Month-38.92%
Income-470.20M PEG- EPS next Q-1.75 Inst Own98.40% Short Float4.58% Perf Quarter-32.98%
Sales331.90M P/S9.84 EPS this Y-118.40% Inst Trans0.27% Short Ratio6.45 Perf Half Y-39.70%
Book/sh11.46 P/B4.16 EPS next Y9.20% ROA-31.90% Target Price128.81 Perf Year-56.09%
Cash/sh8.73 P/C5.46 EPS next 5Y17.20% ROE-51.90% 52W Range47.69 - 114.98 Perf YTD-43.28%
Dividend- P/FCF- EPS past 5Y-1.50% ROI-41.40% 52W High-58.14% Beta1.67
Dividend %- Quick Ratio4.10 Sales past 5Y383.50% Gross Margin94.90% 52W Low0.91% ATR4.36
Employees1119 Current Ratio4.20 Sales Q/Q-19.60% Oper. Margin- RSI (14)27.57 Volatility7.88% 7.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.00% Profit Margin- Rel Volume1.58 Prev Close47.70
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume474.46K Price48.12
Recom2.20 SMA20-23.83% SMA50-30.75% SMA200-38.48% Volume524,172 Change0.89%
Mar-16-22Upgrade Credit Suisse Neutral → Outperform $99 → $105
Feb-11-22Upgrade JP Morgan Neutral → Overweight $132
Sep-30-21Initiated H.C. Wainwright Buy $106
Aug-19-21Initiated UBS Sell $73
Jul-15-21Initiated Guggenheim Neutral
Jun-29-21Upgrade BofA Securities Neutral → Buy $162
Jun-04-21Resumed Robert W. Baird Neutral $109
May-06-21Upgrade Evercore ISI In-line → Outperform $144
May-06-21Upgrade Citigroup Neutral → Buy $160 → $151
Apr-26-21Resumed Credit Suisse Neutral $99
Mar-02-21Resumed Stifel Buy $179
Feb-12-21Downgrade JP Morgan Overweight → Neutral $165
Dec-07-20Downgrade Wedbush Outperform → Neutral $105 → $110
Nov-24-20Resumed Evercore ISI In-line $110
Nov-12-20Downgrade BofA Securities Buy → Neutral $104 → $126
Aug-02-19Resumed Wedbush Outperform $75
Mar-27-19Upgrade Morgan Stanley Equal-Weight → Overweight $68 → $83
Feb-22-19Resumed Raymond James Outperform $80
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18Upgrade Citigroup Sell → Neutral
May-19-22 08:00AM  
May-18-22 11:47AM  
May-17-22 08:00AM  
May-09-22 08:00AM  
May-06-22 11:37AM  
May-05-22 05:25PM  
04:05PM  
May-03-22 05:00PM  
04:05PM  
Apr-29-22 11:06AM  
Apr-27-22 04:01PM  
Apr-26-22 03:01PM  
Apr-25-22 01:18PM  
Apr-22-22 08:00AM  
Apr-21-22 12:52PM  
Apr-20-22 08:00AM  
Apr-13-22 03:34PM  
Mar-02-22 04:01PM  
Feb-16-22 08:45PM  
Feb-11-22 12:02PM  
Feb-10-22 05:25PM  
04:05PM  
Feb-03-22 04:01PM  
03:01PM  
Feb-02-22 04:05PM  
01:38PM  
Jan-28-22 08:24AM  
Jan-24-22 01:38PM  
Jan-10-22 10:28AM  
08:00AM  
Jan-05-22 08:00AM  
Jan-04-22 05:08PM  
Jan-03-22 04:01PM  
Dec-23-21 07:38AM  
Dec-11-21 10:06PM  
Dec-10-21 11:01AM  
Dec-08-21 06:38PM  
Dec-07-21 04:38PM  
Dec-02-21 11:31AM  
10:53AM  
Dec-01-21 04:30PM  
08:00AM  
Nov-29-21 04:40PM  
08:27AM  
08:00AM  
Nov-17-21 03:07PM  
Nov-03-21 11:56AM  
12:01AM  
Nov-02-21 05:25PM  
04:05PM  
Oct-26-21 04:05PM  
Oct-25-21 04:05PM  
Oct-19-21 03:02PM  
Oct-18-21 12:21PM  
08:00AM  
Oct-15-21 10:25AM  
Oct-08-21 10:48AM  
Oct-07-21 08:00AM  
Oct-04-21 04:05PM  
Oct-01-21 04:31PM  
Sep-28-21 12:24PM  
Sep-27-21 04:30PM  
10:39AM  
08:00AM  
Sep-10-21 04:49PM  
Sep-09-21 03:00AM  
Sep-07-21 04:30PM  
08:00AM  
Sep-01-21 04:30PM  
11:30AM  
Aug-31-21 09:19AM  
Aug-23-21 08:30AM  
Aug-17-21 04:05PM  
Aug-13-21 10:53AM  
Aug-04-21 08:30AM  
Aug-03-21 01:22PM  
08:30AM  
Aug-02-21 05:35PM  
04:05PM  
Jul-27-21 05:00PM  
08:00AM  
Jul-22-21 03:03PM  
Jul-13-21 01:16PM  
03:30AM  
Jun-30-21 08:30AM  
Jun-18-21 10:47AM  
Jun-10-21 08:30AM  
Jun-03-21 04:01PM  
11:31AM  
Jun-02-21 06:02AM  
May-26-21 08:31AM  
May-19-21 08:30AM  
May-18-21 04:05PM  
May-14-21 02:33PM  
08:30AM  
May-10-21 04:01PM  
09:02AM  
May-05-21 07:52AM  
06:01AM  
May-04-21 05:35PM  
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huizenga Theodore AlanSVP, Chief Accounting OfficerApr 16Sale84.5513211,16116,914Apr 19 12:56 PM
Kassberg Thomas RichardCBO & EVPMar 11Sale67.0110,281688,930227,559Mar 15 04:33 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 07Sale62.955,140323,56334,438Mar 08 12:25 PM
Fust Matthew KDirectorMar 04Option Exercise40.377,500302,77523,195Mar 08 12:25 PM
Dier MardiCFO & Executive Vice PresidentMar 03Sale64.5542027,11151,808Mar 03 06:12 PM
Dier MardiCFO & Executive Vice PresidentMar 01Sale66.6253435,57538,228Mar 03 06:12 PM
Huang Dennis KarlSee RemarksMar 01Sale66.623,234215,44936,914Mar 03 06:09 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerMar 01Sale66.6284356,16113,229Mar 03 06:09 PM
Pinion John RichardSee RemarksMar 01Sale66.624,498299,65745,266Mar 03 06:10 PM
Harris ErikEVP & Chief Commercial OfficerMar 01Sale66.622,713180,74022,317Mar 03 06:11 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 01Sale66.622,886192,26525,472Mar 03 06:08 PM
Kassberg Thomas RichardCBO & EVPMar 01Sale66.622,374158,156213,840Mar 03 06:07 PM
Bedrosian Camille LEVP and Chief Medical OfficerMar 01Sale66.622,821187,93533,938Mar 03 06:07 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 30Sale66.301,657109,85936,759Feb 01 01:39 PM
Bedrosian Camille LEVP and Chief Medical OfficerOct 14Sale81.1435929,12938,416Oct 18 07:02 PM
Harris ErikEVP & Chief Commercial OfficerOct 14Sale81.1430324,58525,030Oct 18 06:58 PM
Huang Dennis KarlEVP & Chief Tech Ops OfficerOct 14Sale81.1435829,04840,148Oct 18 06:55 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerOct 14Sale81.1414011,36014,072Oct 18 06:53 PM
Kassberg Thomas RichardCBO & EVPOct 14Sale81.1428623,206216,266Oct 18 06:48 PM
Parschauer Karah HerdmanEVP and General CounselOct 14Sale81.1431025,15328,358Oct 18 06:46 PM
Pinion John RichardSee RemarksOct 14Sale81.1435829,04849,764Oct 18 06:41 PM
Dier MardiCFO & Executive Vice PresidentOct 14Sale81.163,261264,66338,762Oct 14 06:33 PM
Dier MardiCFO & Executive Vice PresidentOct 12Sale82.793,477287,86142,023Oct 14 06:33 PM
Kassberg Thomas RichardCBO & EVPSep 30Option Exercise0.31109,73434,018216,552Oct 01 12:57 PM
Parschauer Karah HerdmanEVP and General CounselSep 08Option Exercise54.507,336399,81236,004Sep 09 06:22 PM
Parschauer Karah HerdmanEVP and General CounselSep 08Sale100.657,336738,36828,668Sep 09 06:22 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 02Option Exercise55.002,500137,50041,275Sep 02 06:11 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 02Sale100.182,500250,45038,775Sep 02 06:11 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 01Option Exercise55.002,500137,50041,275Sep 02 06:11 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 01Sale100.032,500250,07538,775Sep 02 06:11 PM
Harris ErikEVP & Chief Commercial OfficerJul 06Sale91.5337534,32425,333Jul 08 11:56 AM
Harris ErikEVP & Chief Commercial OfficerJun 21Sale94.9657254,31725,708Jun 23 05:55 PM
Harris ErikEVP & Chief Commercial OfficerJun 19Sale94.6343741,35326,280Jun 23 05:55 PM
Parschauer Karah HerdmanEVP and General CounselJun 10Sale100.001,329132,90028,668Jun 11 09:08 PM